Korro Bio, Inc.: Phase 2 study started recruiting, 30 planned (Urea Cycle Disorders, Inborn, Urea Cycle Disorders)
Korro Bio, Inc.: Phase 2 study started recruiting, 30 planned (Urea Cycle Disorders, Inborn, Urea Cycle Disorders). Its enrollment of 30 is below the median of 80 (19th percentile). Dated 28 days ago, it is in the active follow-up window. Score 70/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 30 · 19th percentile of 8,879 ClinicalTrialStartPulse records · 0.4x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Korro Bio, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD |
| NCT ID | NCT07773246 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency; Arginase 1 Deficiency; NAGS Deficiency; Carbamylphosphate Synthetase I |
| Intervention types | drug |
| Target enrollment | 30 |
| Site countries | Australia |
| Posted | 2026-08-19 |
| Planned start | 2026-09-28 |
| Event | Started recruiting |
| Event date | 2026-09-28 |
| Last update posted | 2026-10-08 |
| enrollment percentile | 19th of 8,879 (median 80, 0.4x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Korro Bio, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Korro Bio + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-08
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Korro Bio, Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Korro Bio, Inc.'s enrollment: 19th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
70 / 100 Score
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Korro Bio, Inc.?
Korro Bio, Inc.'s Phase 2 study (NCT07773246) in Urea Cycle Disorders, Inborn, first posted 2026-08-19: started recruiting (2026-09-28), in an update posted 2026-10-08.
How does Korro Bio, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 30 is below the median (19th percentile); smaller records often move faster and face less competition. It is 28 days old, still within a typical 45-day follow-up window. Its Score of 70/100 puts it among the stronger signals in this feed.
Korro Bio, Inc. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Korro Bio, Inc. | NONUS | 30 | 19th | 2026-10-08 |
| BeOne Medicines | NONUS | 100 | 60th | 2026-11-03 |
| Nurix Therapeutics, Inc. | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 166 | 73rd | 2026-11-03 |
Related records
- Nurix Therapeutics, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Apogee Therapeutics, Inc.
- Janssen Research & Development, LLC
- BeOne Medicines
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Korro Bio, Inc. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Korro Bio, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.